Biomarkers and early-onset acute kidney injury in critically ill COVID-19 patients, a prospective monocentric observational study.

Background: The present study evaluated the diagnostic and prognostic value of biomarkers, including soluble forms of the receptor for advanced glycation end-products (s-RAGE), soluble urokinase plasminogen activator receptor (SuPAR), and others, for the occurrence of early-onset acute kidney injury (EO-AKI), EO-AKI non-recovery, day-90 major adverse kidney events (MAKE-90), and day-90 mortality in critically ill patients with Coronavirus Disease-19 (Covid-19).

Methods: A single-center, prospective study was conducted at the University Hospital of Clermont-Ferrand, France, between March 2020 and February 2021. The study included adult patients suffering from severe pneumonia caused by the SARS-CoV-2 virus, who were admitted to the hospital's intensive care unit.